Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.75 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | RRM1 | P23921 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11780948 | 0.98 | EPHX1 (0.79) | EPHX1DPP7RRM1EPHX2CASP2 | |
| SCHEMBL10558436 | 0.93 | EPHX1 (0.68) | EPHX1DPP7RRM1EPHX2 | |
| SCHEMBL17740004 | 0.91 | EPHX1 (0.75) | EPHX1DPP7RRM1EPHX2CASP2 | |
| SCHEMBL11780869 | 0.89 | EPHX1 (0.79) | EPHX1RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11779199 | 0.89 | EPHX1 (0.79) | EPHX1RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11780971 | 0.89 | EPHX1 (0.79) | EPHX1RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11778781 | 0.89 | EPHX1 (0.79) | EPHX1DPP7RRM1EPHX2CASP2 | |
| SCHEMBL21538794 | 0.89 | EPHX1 (0.79) | EPHX1RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11778026 | 0.89 | EPHX1 (0.79) | EPHX1RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL11779920 | 0.89 | EPHX1 (0.79) | EPHX1DPP7RRM1EPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | EPHX1 634/4885DPP7 2054/4885RRM1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.